A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

ICOS Corporation

Status and phase: Completed; Phase 2

Conditions: Pneumonia; Sepsis

Treatments: Drug: Recombinant Chimeric Monoclonal Antibody

Study type: Interventional

Funder types: Industry

Identifiers

NCT00042588

EPN01

Details and patient eligibility

About

The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Current diagnosis of community-acquired pneumonia.
• Evidence of systemic inflammatory response to infection.

Exclusion criteria

• Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator.
• Presence of organ failure.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind